| 1. |
Van Cutsem E, Nordlinger B, Adam R, et al. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer, 2006, 42(14): 2212-2221.
|
| 2. |
www.livermetsurvey.org.
|
| 3. |
Xu J, Qin X, Wang J, et al. Chinese guidelines for the diagnosis and comprehensive treatment of hepatic metastasis of colorectal cancer. J Cancer Res Clin Oncol, 2011, 137(9): 1379-1396.
|
| 4. |
Jaeck D, Oussoultzoglou E, Rosso E, et al. A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases. Ann Surg, 2004, 240(6): 1037-1049, 1049-1051.
|
| 5. |
Clavien PA, Petrowsky H, DeOliveira ML, et al. Strategies for safer liver surgery and partial liver transplantation. N Engl J Med, 2007, 356(15): 1545-1559.
|
| 6. |
Schnitzbauer A A, Lang S A, Goessmann H, et al. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg, 2012, 255(3): 405-414.
|
| 7. |
Vivarelli M, Vincenzi P, Montalti R, et al. ALPPS Procedure for extended liver resections: a single centre experience and a systematic review. PLoS One, 2015, 10(12): e0144019.
|
| 8. |
Ruers T, Punt C, Van Coevorden F, et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol, 2012, 23(10): 2619-2626.
|
| 9. |
Tanis E, Nordlinger B, Mauer M, et al. Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983. Eur J Cancer, 2014, 50(5): 912-919.
|
| 10. |
Sotirchos VS, Petrovic LM, G?nen M, et al. Colorectal cancer liver metastases: biopsy of the ablation zone and margins can be used to predict oncologic outcome. Radiology, 2016, 280(3): 949-959.
|
| 11. |
Han Y, Yan D, Xu F, et al. Radiofrequency ablation versus liver resection for colorectal cancer liver metastasis: an updated systematic review and meta-analysis. Chin Med J (Engl), 2016, 129(24): 2983-2990.
|
| 12. |
Mahnken AH, Pereira PL, de Baère T. Interventional oncologic approaches to liver metastases. Radiology, 2013, 266(2): 407-430.
|
| 13. |
Diaz-Nieto R, Fenwick S, Malik H, et al. Defining the optimal use of ablation for metastatic colorectal cancer to the liver without high-level evidence. Curr Treat Options Oncol, 2017, 18(2): 8.
|
| 14. |
Petre EN, Sofocleous C. Thermal ablation in the management of colorectal cancer patients with oligometastatic liver disease. Visc Med, 2017, 33(1): 62-68.
|
| 15. |
Karanicolas PJ, Jarnagin WR, Gonen M, et al. Long-term outcomes following tumor ablation for treatment of bilateral colorectal liver metastases. JAMA Surg, 2013, 148(7): 597-601.
|
| 16. |
Timmerman RD, Herman J, Cho LC. Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice. J Clin Oncol, 2014, 32(26): 2847-2854.
|
| 17. |
Scorsetti M, Arcangeli S, Tozzi A, et al. Is stereotactic body radiation therapy an attractive option for unresectable liver metastases? A preliminary report from a phase 2 trial. Int J Radiat Oncol Biol Phys, 2013, 86(2): 336-342.
|
| 18. |
Tree AC, Khoo VS, Eeles RA, et al. Stereotactic body radiotherapy for oligometastases. Lancet Oncol, 2013, 14(1): e28-e37.
|
| 19. |
Zhang SY, Zhu GY, Li G, et al. Application of stereotactic body radiation therapy to cancer liver metastasis. Cancer Lett, 2016, 379(2): 225-229.
|
| 20. |
Mutsaers A, Greenspoon J, Walker-Dilks C, et al. Systematic review of patient reported quality of life following stereotactic ablative radiotherapy for primary and metastatic liver cancer. Radiat Oncol, 2017, 12(1): 110.
|
| 21. |
Palma DA, Louie AV, Rodrigues GB. New strategies in stereotactic radiotherapy for oligometastases. Clin Cancer Res, 2015, 21(23): 5198-5204.
|
| 22. |
Kim H, Gill B, Beriwal S, et al. Cost-effectiveness analysis of stereotactic body radiation therapy compared with radiofrequency ablation for inoperable colorectal liver metastases. Int J Radiat Oncol Biol Phys, 2016, 95(4): 1175-1183.
|
| 23. |
Kemeny NE, Melendez FD, Capanu M, et al. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol, 2009, 27(21): 3465-3471.
|
| 24. |
Chan DL, Alzahrani NA, Morris DL, et al. Systematic review and meta-analysis of hepatic arterial infusion chemotherapy as bridging therapy for colorectal liver metastases. Surg Oncol, 2015, 24(3): 162-171.
|
| 25. |
Lévi FA, Boige V, Hebbar M, et al. Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV. Ann Oncol, 2016, 27(2): 267-274.
|
| 26. |
Goéré D, Deshaies I, de Baere T, et al. Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases. Ann Surg, 2010, 251(4): 686-691.
|
| 27. |
de Baere T, Tselikas L, Yevich S, et al. The role of image-guided therapy in the management of colorectal cancer metastatic disease. Eur J Cancer, 2017, 75: 231-242.
|
| 28. |
Zacharias AJ, Jayakrishnan TT, Rajeev R, et al. Comparative effectiveness of hepatic artery based therapies for unresectable colorectal liver metastases: a meta-analysis. PLoS One, 2015, 10(10): e0139940.
|
| 29. |
Onaitis MW, Petersen RP, Haney JC, et al. Prognostic factors for recurrence after pulmonary resection of colorectal cancer metastases. Ann Thorac Surg, 2009, 87(6): 1684-1688.
|
| 30. |
Meimarakis G, Spelsberg F, Angele M, et al. Resection of pulmonary metastases from colon and rectal cancer: factors to predict survival differ regarding to the origin of the primary tumor. Ann Surg Oncol, 2014, 21(8): 2563-2572.
|
| 31. |
de Baère T, Aupérin A, Deschamps F, et al. Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1 037 metastases. Ann Oncol, 2015, 26(5): 987-991.
|
| 32. |
Wild AT, Yamada Y. Treatment options in oligometastatic disease: stereotactic body radiation therapy - focus on colorectal cancer. Visc Med, 2017, 33(1): 54-61.
|
| 33. |
Siva S, Slotman BJ. Stereotactic ablative body radiotherapy for lung metastases: where is the evidence and what are we doing with it? Semin Radiat Oncol, 2017, 27(3): 229-239.
|
| 34. |
de Baere T, Tselikas L, Gravel G, et al. Lung ablation: best practice/results/response assessment/role alongside other ablative therapies. Clin Radiol, 2017, 72(8): 657-664.
|
| 35. |
Hornung M, Werner JM, Schlitt HJ. Applications of hyperthermic intraperitoneal chemotherapy for metastatic colorectal cancer. Expert Rev Anticancer Ther, 2017, 17(9): 841-850.
|
| 36. |
Hall B, Padussis J, Foster JM. Cytoreduction and hyperthermic intraperitoneal chemotherapy in the management of colorectal peritoneal metastasis. Surg Clin North Am, 2017, 97(3): 671-682.
|
| 37. |
李群, 黃鏡. 卵巢切除術在結直腸癌綜合治療中的研究進展. 中華結直腸疾病電子雜志, 2017, 6(4): 60-62.
|
1/5
WeChat